VIDEO: Study evaluating ‘first-of-its-kind’ C1q inhibitor in advanced dry AMD

ByNancy Holekamp, MD

BySavannah Demko

In a Healio video interview, Nancy M. Holekamp, MD, director of retina services at Pepose Vision Institute in St. Louis, discussed her ASRS presentation on ANX007, a novel C1q inhibitor for advanced dry age-related macular degeneration.

“With selective inhibition of C1q, you also shut down C3 and C5 as well as other classical pathway components C4 and C9, so there is a rationale to target the classical pathway, and this is the first molecule that hopes to do so,” Holekamp said.

Holekamp discussed an ongoing phase 2 clinical trial evaluating the effects of ANX007 (Annexon Biosciences) in patients with geographic atrophy.

“The results are anticipated in 2023, but this is a first-of-its-kind new attempt to target the classical pathway for treating patients with advanced dry age-related macular degeneration,” she said.

Published by:

Sources/Disclosures

Collapse

Source:

Holekamp N. Evaluating ANX007, a novel C1q inhibitor, in the treatment of geographic atrophy (GA) secondary to age-related macular degeneration: The ARCHER study. Presented at: American Society of Retina Specialists meeting; Oct. 8-12, 2021; San Antonio.

Disclosures: Holekamp reports being a paid consultant for Acucela, Allergan, Annexon, Clearside Biomedical, Gemini, Genentech, Gyroscope, Katalyst Surgical, Lineage Cell Therapeutics, Nacuity, Notal Vision, Novartis, Regeneron and Stealth Biosciences; being on the speakers bureau for Allergan, Genentech, Novartis, Regeneron and Spark; doing contracted research for Gemini, Genentech, Gyroscope and Notal Vision; and holding intellectual property/patent with Katalyst Surgical.

Take Homes in AMD

Read more

VIDEO: Study evaluating ‘first-of-its-kind’ C1q inhibitor in advanced dry AMD

Related Content